Aeglea Biotherapeutics (AGLE) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating on Aeglea Biotherapeutics (AGLE) today and set a price target of $17.00. The company’s shares closed last Tuesday at $7.65.
According to TipRanks.com, White is a 5-star analyst with an average return of 25.0% and a 51.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.
Aeglea Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $16.20, an 116.9% upside from current levels. In a report issued on September 14, LifeSci Capital also maintained a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.38 and a one-year low of $3.50. Currently, Aeglea Biotherapeutics has an average volume of 311.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.